142 related articles for article (PubMed ID: 17022460)
1. [Identification of AGR2 protein, a novel potential cancer marker, using proteomics technologies].
Kovalev LI; Shishkin SS; Khasigov PZ; Dzeranov NK; Kazachenko AV; Toropygin IIu; Mamykina SV
Prikl Biokhim Mikrobiol; 2006; 42(4):480-4. PubMed ID: 17022460
[TBL] [Abstract][Full Text] [Related]
2. [New approaches to molecular diagnosis of prostatic cancer].
Kovalev LI; Shishkin SS; Khasigov PZ; Dzeranov NK; Kazachenko AV; Kovaleva MA; Toropygin IIu; Eremina LS; Grachev SV
Urologiia; 2006; (5):16-9. PubMed ID: 17444146
[TBL] [Abstract][Full Text] [Related]
3. Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine.
Wayner EA; Quek SI; Ahmad R; Ho ME; Loprieno MA; Zhou Y; Ellis WJ; True LD; Liu AY
Prostate; 2012 Jun; 72(9):1023-34. PubMed ID: 22072305
[TBL] [Abstract][Full Text] [Related]
4. An efficient method for native protein purification in the selected range from prostate cancer tissue digests.
Ahmad R; Nicora CD; Shukla AK; Smith RD; Qian WJ; Liu AY
Chin Clin Oncol; 2016 Dec; 5(6):78. PubMed ID: 28061542
[TBL] [Abstract][Full Text] [Related]
5. SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progression.
Malik G; Rojahn E; Ward MD; Gretzer MB; Partin AW; Semmes OJ; Veltri RW
Prostate; 2007 Oct; 67(14):1565-75. PubMed ID: 17705230
[TBL] [Abstract][Full Text] [Related]
6. MALDI mass spectrometry in prostate cancer biomarker discovery.
Flatley B; Malone P; Cramer R
Biochim Biophys Acta; 2014 May; 1844(5):940-9. PubMed ID: 23831156
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery.
Tanase CP; Codrici E; Popescu ID; Mihai S; Enciu AM; Necula LG; Preda A; Ismail G; Albulescu R
Oncotarget; 2017 Mar; 8(11):18497-18512. PubMed ID: 28061466
[TBL] [Abstract][Full Text] [Related]
8. New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics.
Paweletz CP; Liotta LA; Petricoin EF
Urology; 2001 Apr; 57(4 Suppl 1):160-3. PubMed ID: 11295617
[TBL] [Abstract][Full Text] [Related]
9. Analysis of prostatic fluid: evidence for the presence of a prospective marker for prostatic cancer.
Grover PK; Resnick MI
Prostate; 1995 Jan; 26(1):12-8. PubMed ID: 7531324
[TBL] [Abstract][Full Text] [Related]
10. Prostate carcinoma tissue proteomics for biomarker discovery.
Zheng Y; Xu Y; Ye B; Lei J; Weinstein MH; O'Leary MP; Richie JP; Mok SC; Liu BC
Cancer; 2003 Dec; 98(12):2576-82. PubMed ID: 14669276
[TBL] [Abstract][Full Text] [Related]
11. [Capillary electrophoresis coupled to mass spectrometry for proteome analysis. An innovative diagnostic method for prostate and bladder cancer].
Wittke S; Schiffer E; Bauer HW
Urologe A; 2007 Jul; 46(7):733-9. PubMed ID: 17318473
[TBL] [Abstract][Full Text] [Related]
12. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype.
Kani K; Malihi PD; Jiang Y; Wang H; Wang Y; Ruderman DL; Agus DB; Mallick P; Gross ME
Prostate; 2013 Feb; 73(3):306-15. PubMed ID: 22911164
[TBL] [Abstract][Full Text] [Related]
13. In the search of novel urine biomarkers for the early diagnosis of prostate cancer. Intracellular or secreted proteins as the target group? Where and how to search for possible biomarkers useful in the everyday clinical practice.
Katafigioti A; Katafigiotis I; Sfoungaristos S; Alamanis C; Stravodimos K; Anastasiou I; Roumelioti E; Duvdevani M; Constantinides C
Arch Ital Urol Androl; 2016 Oct; 88(3):195-200. PubMed ID: 27711093
[TBL] [Abstract][Full Text] [Related]
14. Parafilm-assisted microdissection: a sampling method for mass spectrometry-based identification of differentially expressed prostate cancer protein biomarkers.
Quanico J; Franck J; Gimeno JP; Sabbagh R; Salzet M; Day R; Fournier I
Chem Commun (Camb); 2015 Mar; 51(22):4564-7. PubMed ID: 25490716
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology.
Fredolini C; Meani F; Luchini A; Zhou W; Russo P; Ross M; Patanarut A; Tamburro D; Gambara G; Ornstein D; Odicino F; Ragnoli M; Ravaggi A; Novelli F; Collura D; D'Urso L; Muto G; Belluco C; Pecorelli S; Liotta L; Petricoin EF
AAPS J; 2010 Dec; 12(4):504-18. PubMed ID: 20549403
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers for prostate cancer.
Schiffer E
World J Urol; 2007 Dec; 25(6):557-62. PubMed ID: 17690889
[TBL] [Abstract][Full Text] [Related]
17. Proteomics in cancer.
Reymond MA; Schlegel W
Adv Clin Chem; 2007; 44():103-42. PubMed ID: 17682341
[TBL] [Abstract][Full Text] [Related]
18. Proteomics of breast cancer for marker discovery and signal pathway profiling.
Hondermarck H; Vercoutter-Edouart AS; Révillion F; Lemoine J; el-Yazidi-Belkoura I; Nurcombe V; Peyrat JP
Proteomics; 2001 Oct; 1(10):1216-32. PubMed ID: 11721634
[TBL] [Abstract][Full Text] [Related]
19. Expression of store-operated channel components in prostate cancer: the prognostic paradox.
Perrouin Verbe MA; Bruyere F; Rozet F; Vandier C; Fromont G
Hum Pathol; 2016 Mar; 49():77-82. PubMed ID: 26826413
[TBL] [Abstract][Full Text] [Related]
20. Mass spectrometry-based expression profiling of clinical prostate cancer.
Wright ME; Han DK; Aebersold R
Mol Cell Proteomics; 2005 Apr; 4(4):545-54. PubMed ID: 15695425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
